What is Unity Biotechnology's focus?

Unity Biotechnology is focused on developing new medicines that harness the pathways of aging biology, with a particular focus on retinal diseases.

What is cellular senescence, and how is Unity addressing it?

Cellular senescence is the underlying biology behind many chronic and inflammatory diseases that take a toll on health and quality of life as we age. Unity is at the forefront of developing a new class of therapeutics that aim to restore diseased tissue to a healthier state by targeting cellular senescence.

Voyager DB

Deep data on millions of local businesses, with verified decision-makers to reveal.

Contact Research

Hand-built prospect lists from human researchers, delivered in 24 hours.

People Search

Find owners and decision-makers by job title, seniority and department.

Chrome Extension

Coldlytics in your browser - prospect any business as you browse the web.

Integrations

Instantly, Smartlead, lemlist, Clay, HighLevel, plus Claude and ChatGPT over MCP.

Voyager DBDeep data on millions of local businesses, with verified decision-makers to reveal.Contact ResearchHand-built prospect lists from human researchers, delivered in 24 hours.People SearchFind owners and decision-makers by job title, seniority and department.Chrome ExtensionColdlytics in your browser - prospect any business as you browse the web.IntegrationsInstantly, Smartlead, lemlist, Clay, HighLevel, plus Claude and ChatGPT over MCP.

PricingPricing AgenciesAgencies BlogBlog

LoginLogin

Unity Biotechnology

$150.0K revenue • 1 employees • 285 E Grand Ave., South San Francisco, CA, 94080, United States

Last Updated Feb 19, 2026

Own this business? Claim & update this listing →

Company Overview

Company Name

Unity Biotechnology

Address

285 E Grand Ave., South San Francisco, CA, 94080, United States

Website

unitybiotechnology.com

Phone

(650) 416-1192

Approx. Annual Revenue

$0.1M

Employees

Established

2014

About Unity Biotechnology

Unity Biotechnology is a United States-based company focused on developing new medicines to harness the biology of aging and address retinal diseases. The company's lead senolytic candidate, UBX1325, has shown promising results in a Phase 2 study for diabetic macular edema, demonstrating sustained and clinically meaningful improvements in vision.

Biotech & Life Sciences Companies near South San Francisco, CA

Browse all Biotech & Life Sciences companies in California →

Frequently Asked Questions about Unity Biotechnology

Technologies Used

Bootstrap

Key Decision Makers

David Buttaro Executive Director

Desiree McKenzie Clinical Trial Manager II

Sharon Klier Study Contact

Clinical Operations Study Contact